In the claims:

1. (Currently Amended) A <u>crystalline</u> calcium salt of <u>(E)-(3R,5S)-(+)-7-[3-(4-fluorophenyl)-1-(1-methyl-ethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid the formula</u>

$$R_3$$
 R_4
 R_6
 R_6
 R_7
 R_8
 R_1
 R_8
 R_1
 R_8
 R_1
 R_8
 R_1
 R_1
 R_1
 R_2
 R_3
 R_4
 R_6
 R_7
 R_8
 R_9
 R_9

wherein R₁ is isopropyl; R₂ is fluorine, R₃, R₄, R₅ and R₆ are independently hydrogen; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer or a hydrate thereof which has a powder X-ray diffraction pattern with maxima at 2θ values of 5.3, 11.8, 13.9, 17.5, 19.1, 22.0 and 23.1 and which has a melting point of about 220°C.

2-12. (Cancelled)

- 13. (Currently Amended) A pharmaceutical composition, comprising: a therapeutically effective amount of [[a]] the calcium salt according to claim [[7]] 1 in combination with one or more pharmaceutically acceptable carriers.
- 14. (Currently Amended) A method for treating hypercholesterolemia, hyperlipoproteinemia, dyslipidemia and atherosclerosis, comprising: administering to a mammal in need thereof a therapeutically effective amount of [[a]] the calcium salt according to claim [[7]] 1.